Oragenics to Participate in the World Vaccine Congress Washington

Article content material

TAMPA, Fla. — Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Firm”), a biotechnology firm devoted to combating infectious ailments together with COVID-19, pronounces that Kim Murphy, Chief Government Officer, might be collaborating within the World Vaccine Congress Washington, being held April 3-6, 2023, in Washington, D.C.

Ms. Murphy might be holding conferences to focus on the corporate’s lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, and to discover partnering alternatives. Oragenics not too long ago reported favorable toxicology outcomes confirming a security and immunogenicity profile for NT-CoV2-1 that help plans to submit regulatory filings to proceed to a Part 1 medical examine. Oragenics believes an intranasal COVID-19 vaccine holds a number of potential advantages in contrast with injectable vaccines, together with concentrating on mucosal immunity, lowering transmission and providing a needle-free different for sufferers.

Article content material

Article content material

“I’m excited to participate within the World Vaccine Congress this 12 months and share our progress towards a extremely differentiated intranasal COVID-19 vaccine,” mentioned Ms. Murphy. “We anticipate sturdy curiosity amongst vaccine consultants on this distinctive program and stay up for advancing to Part 1 medical trials in people.”

Please contact tpatel@lhai.com or kmurphy@oragenics.com if you’re eager about scheduling a gathering.

Earlier this month Oragenics entered into an unique international license settlement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301. The corporate is presently evaluating formulation choices for NT-CoV2-1 and is assessing varied regulatory pathways to advance this program effectively and thoughtfully.

In December 2022 Oragenics reported no toxicity indicators or adversarial occasions from its GLP toxicology examine in rabbits evaluating the security and immunogenicity of NT-CoV2-1. The examine targets had been to guage potential toxicity following repeated intranasal administration on the maximal dose anticipated for use in people, and to substantiate the immunogenicity of the vaccine.

Oragenics beforehand revealed constructive preclinical information in Scientific Reports, a Nature journal, demonstrating that intranasal administration of NT-CoV2-1 induced strong antigen-specific IgG and IgA titers within the blood and lungs of mice, and lowered viral load beneath the restrict of detection in a hamster SARS-CoV-2 problem mannequin. In each mice and hamsters, the antibodies had sturdy neutralizing exercise, stopping the mobile binding of the viral spike protein based mostly on the ancestral reference pressure and variants of concern.

Concerning the World Vaccine Congress

The World Vaccine Congress is the most important, most established assembly devoted to vaccines. From primary analysis to business manufacture, this one assembly covers the complete vaccine worth chain the place science, authorities and producers all come collectively to create groundbreaking progress.

About Oragenics, Inc.

Oragenics, Inc. is a development-stage firm devoted to combating infectious ailments, together with these attributable to coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to forestall COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein analysis licensed from the Nationwide Institutes of Well being (NIH) and the Nationwide Analysis Council of Canada (NRC) with a concentrate on lowering viral transmission and providing a extra patient-friendly intranasal administration. Its lantibiotics program contains a novel class of antibiotics towards micro organism which have developed resistance to business antibiotics. For extra details about Oragenics, please go to www.oragenics.com.

Article content material

Ahead-Trying Statements

This communication accommodates “forward-looking statements” throughout the which means of the protected harbor provisions of the U.S. Personal Securities Litigation Reform Act of 1995. These forward-looking statements are based mostly on administration’s beliefs and assumptions and knowledge presently obtainable. The phrases “consider,” “anticipate,” “anticipate,” “intend,” “estimate,” “venture” and comparable expressions that don’t relate solely to historic issues establish forward-looking statements. Buyers ought to be cautious in counting on forward-looking statements as a result of they’re topic to a wide range of dangers, uncertainties, and different elements that might trigger precise outcomes to vary materially from these expressed in any such forward-looking statements. These elements embrace, however will not be restricted to, the next: the Firm’s skill to acquire crucial funding, non-dilutive or in any other case, for the event of the vaccine and lantibiotic product candidates; the Firm’s skill to advance the event of its vaccine candidate and lantibiotics candidate beneath the timelines and in accord with the milestones it tasks; the regulatory utility course of, analysis and improvement phases, and future medical information and evaluation referring to vaccines and lantibiotics, together with any conferences, selections by regulatory authorities, such because the FDA and Canadian regulatory authorities and investigational evaluation boards, whether or not favorable or unfavorable; the potential utility of our vaccine candidate to variants and different coronaviruses; the Firm’s skill to acquire, keep and implement crucial patent and different mental property safety and license agreements; the character of competitors and improvement referring to COVID-19 immunization and therapeutic therapies and demand for vaccines and antibiotics; the Firm’s expectations as to the result of preclinical research, nasal administration, transmission, manufacturing, storage and distribution; different potential adversarial impacts reminiscent of delays in regulatory evaluation, manufacturing delays and provide chain points, adversarial impacts on healthcare techniques and disruption of the worldwide financial system; the flexibility to maintain compliance with our trade itemizing necessities; and basic financial and market circumstances and dangers, in addition to different uncertainties described in our filings with the U.S. Securities and Trade Fee. All data set forth on this press launch is as of the date hereof. It’s best to contemplate these elements in evaluating the forward-looking statements included on this press launch and never place undue reliance on such statements. We don’t assume any obligation to publicly present revisions or updates to any forward-looking statements, whether or not on account of new data, future developments or in any other case, ought to circumstances change, besides as in any other case required by regulation.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20230329005760/en/

Contacts

Oragenics, Inc.
Janet Huffman, Chief Monetary Officer
813-286-7900
jhuffman@oragenics.com

LHA Investor Relations
Tirth T. Patel
212-201-6614
tpatel@lhai.com

#distro